Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of ...

Individuals with genetic diseases have an increased chance of lower quality of life. However, a new technology has been developed that could edit DNA and take out possible mutations resolving genetic ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

The Food and Drug Administration (FDA) approved the gene therapy Casgevy in December, which uses CRISPR/Cas9 genome editing technology to treat sickle-cell disease (SCD) in patients twelve years and ...

Researchers are applying CRISPR-Cas9 as a stoichiometric binding tool to improve NGS library normalization. The ...

Babcock University has intensified efforts to advance biomedical research and food security by hosting a three-day gene editing workshop focused on the transformative potential of CRISPR-Cas9 ...